Cagent Vascular Presents Positive Results from the PRELUDE Study at LINC 2018

WAYNE, Pa.--()--Cagent Vascular, a developer of next generation technology for vessel dilatation in cardiovascular interventions announces positive results from the First-in-Human PRELUDE Study. Dr. Andrew Holden (Auckland, New Zealand), Principal Investigator, presented 30-day and preliminary 6-month results using the FDA 510(k) cleared Serranator® Alto PTA Serration Balloon Catheter at the Leipzig Interventional Course last week.

The PRELUDE Study is a prospective, single-arm, multicenter feasibility study designed to show safety and efficacy of the Serranator® device used in critical lesions in the superficial femoral artery (SFA) and/or popliteal arteries. The study enrolled 25 subjects at centers in New Zealand and Europe.

“The fascinating part of the trial is that although we had patients, by definition, who were excluded with severe calcification, there was a significant core lab adjudicated group of persons who had lesions with moderate to severe calcification. We could achieve luminal gain to nominal using very low pressures in that subgroup which tells us that this is something quite different from plain balloon angioplasty. Not only being able to dilate these vessels to nominal, which is an achievement on its own, but to do it without a significant incidence of dissection is an achievement. Although the numbers are small this is a really encouraging sign that the serration mechanism of action is a very different way of treating the artery,” said Dr. Holden.

The Serranator device has four external metal serrated strips embedded on a semi-compliant balloon. The Serranator’s unique serration technology is designed to create multiple longitudinal lines of interrupted micro-serrations along the arterial surface to aid arterial expansion. The serrations are responsive to the balloon’s energy, enabling predictable and controlled lumen expansion along the lines. The device received FDA 510(k) clearance and CE Marking in 2017.

The primary objective was technical feasibility of using the Serranator in critical SFA or popliteal artery lesions. The secondary objective was the feasibility of using Optical Coherence Tomography (OCT) and or Intravascular Ultrasound (IVUS) in a sub-set (n=10) of subjects to evaluate the presence of serrations. Eighty percent (n=20) of lesions treated were in the SFA. Fifty six percent of lesions treated had moderate to severe calcification and 32% were Chronic Total Occlusions (CTO). The pre-diameter stenosis was 87.6% with a final diameter stenosis of 22.7% using just the Serranator device. The mean lumen gain was 3.45 mm in the severe group (n=7) requiring just 8.57 ATM of maximum pressure vs 3.33 mm in the none to moderate group (n=18) using only 7.67 ATM. There were no flow limiting dissections and only 1 bailout stent (4%). All subjects who underwent IVUS or OCT showed a serration effect as analyzed by the core lab. There was 100% patency at 30-days as assessed by Duplex Ultrasound (DUS) and 100% freedom from TLR at 30-days and 6-months.

“In this current era of increasing vessel complexity and economic pricing pressures, treatments need to be effective but not complex. The Serranator is positioned to be the off-the-shelf, 'workhorse' solution for SFA and popliteal treatment both for the inpatient and outpatient settings,” says Carol A. Burns, President and CEO. “We believe these results are a positive signal that the same mechanism of action will work for the treatment of critical limb ischemia where there is an even greater unmet need for a device like ours.”

Co-founder and Chief Medical Officer, Dr. Peter Schneider commented, “We are impressed with the device performance and especially with its ability to cross very tight lesions. The catheter’s inherent flexibility and low-profile design, along with its enhanced pushability specific to the BTK device, are highly desired attributes for the challenging treatment of diseased infrapopliteal arteries. We expect to begin the PRELUDE-BTK study later this year.”

About the PRELUDE Study

For more information regarding the PRELUDE Study visit

About Cagent Vascular

Cagent Vascular is leading the way for next generation technology for vessel dilatation. It is the second cardiovascular company formed by co-founders Carol Burns, President and CEO, Peter Schneider, MD, Vascular Surgeon, Chief Medical Officer and Robert Giasolli, VP of Research and Development. Visit


Cagent Vascular, LLC
Lauren Pfeiffer, 610-688-2006

Release Summary

Cagent Vascular, developer of the Serranator PTA Serration Balloon Catheter, announces positive first-in-human results from PRELUDE Study at LINC 2018


Cagent Vascular, LLC
Lauren Pfeiffer, 610-688-2006